BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 32221325)

  • 1. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
    Adachi N; Ayukawa Y; Yasunami N; Furuhashi A; Imai M; Sanda K; Atsuta I; Koyano K
    Sci Rep; 2020 Mar; 10(1):5620. PubMed ID: 32221325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw.
    Sanda K; Ayukawa Y; Yasunami N; Adachi N; Furuhashi A; Imai M; Matsunaka K; Koyano K
    J Periodontol; 2022 Jun; 93(6):837-846. PubMed ID: 34510440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing.
    Zheng Y; Dong X; Chen S; He Y; An J; Liu M; He L; Zhang Y
    BMC Oral Health; 2023 Jan; 23(1):14. PubMed ID: 36627695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats.
    Bolette A; Lecloux G; Rompen E; Albert A; Kerckhofs G; Lambert F
    J Craniomaxillofac Surg; 2019 Feb; 47(2):349-356. PubMed ID: 30595476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
    Zhao N; Li QX; Wang YF; Qiao Q; Huang HY; Guo CB; Guo YX
    BMC Oral Health; 2023 May; 23(1):330. PubMed ID: 37245004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy.
    Monteiro CGJ; Vieira EM; Emerick C; Azevedo RS; Pascoal VAB; Homsi N; Lins RX
    Clin Oral Investig; 2021 Dec; 25(12):6653-6659. PubMed ID: 33895916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-rhBMP-2 Containing Artificial Bone Graft Administration.
    Tanaka Y; Aung KT; Ono M; Mikai A; Dang AT; Hara ES; Tosa I; Ishibashi K; Ono-Kimura A; Nawachi K; Kuboki T; Oohashi T
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further development of the MRONJ minipig large animal model.
    Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S
    J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.
    Hadad H; Matheus HR; Pai SI; Souza FA; Guastaldi FPS
    Arch Oral Biol; 2024 Mar; 159():105875. PubMed ID: 38160519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
    Kuroshima S; Sasaki M; Murata H; Sawase T
    Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.